Search

Selected EMA news

November 2024New medicines recommended for approval
Eltrombopag Viatris (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C (disease in which patients have low levels of blood platelets)

Alhemo (concizumab)
Prevention of bleeding in patients with hemophilia A…

Read more

May 8 - International Thalassaemia Day

Every year on the 8th May, Thalassaemia International Federation commemorates the International Thalassaemia Day and organises activities for raising awareness about the genetic blood disorder of thalassaemia, on general topics regarding its prevention, management and cure.

Read more

Meet Willem Fibbe, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been involved in EHA over a period of twenty years, starting as counselor from 2000-2004.

Read more

Meet Willem Fibbe, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been involved in EHA over a period of twenty years, starting as counselor from 2000-2004.

Read more

EHA Mentorship Program eligibility

Before applying for the EHA Mentorship Program, please consider the eligibility criteria on this page. You should also read our policy on life events.

Read more

Turning thoughts into reality

Turning thoughts into reality
By Dr Adi Zoref (@ZorefAdi)

I am an Israeli physician, trained in internal medicine. During my residency rotation in hematology at Meir Medical Center, I met a patient who changed my life.

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more